Home » Customer Testimonials » Elevate Bio

Elevate Bio.

This CDMO is continuously evaluates cutting-edge technologies to help partners develop cell and gene therapies more efficiently. In February 2025, they acquired IRO® to test its ability to integrate into their advanced manufacturing ecosystem and accelerate scalable, high-performance CGT production for their customers.

  • "IRO is an extremely robust T cell platform for activation, transduction and expansion. The system effectively checks the boxes for automation and connectivity, scalability and flexibility. It is intuitive, requiring little training and is easily adopted. Shows consistent robust performance, lowers cost of goods and reduces vein to vein time to get more batches to more patients faster."

  • "We observed the following results with IRO: 96% cell viability, 4.31B total cell yield by Day 7, 48.8% transduction efficiency vs 26.4% for the control, quicker activation observed in the IRO versus the control"

Partner Data

Explore ElevateBio’s IRO data here.

See the data

Ori Spotlight Podcast

Mike Paglia from ElevateBio joined Jason C. Foster on the Ori Spotlight Podcast in July 2022, where they discuss how ElevateBio supports the cell and gene therapy industry, the long-term benefits of digital manufacturing processes, and the importance of removing the cost barrier to CGT.

Listen here

Webinar

Learn about the different approaches this CDMO is leveraging to scaling CGT manufacturing, featuring Jeffrey Cram from ElevateBio. This event took place in August 2025.

Learn more